← Back to headlines
Hims & Hers Health Stock Rises on FDA Review of Peptide Therapies
Hims & Hers Health saw its stock jump following news of the FDA's review of compounded peptide therapies, indicating market reaction to potential regulatory developments in the wellness sector.
16 Apr, 21:17 — 16 Apr, 21:17
Sources
Showing 1 of 1 sources
Related Stories
RFK Jr. Allegedly Requested Removal of Measles Deaths From CDC Tally
38m ago
Pentagon Temporarily Rescinds Mandatory Testosterone Screening Guidance for Troops
1h ago
Experts Warn Obsessive Sleep Tracking May Disrupt Rest Quality
2h ago
UNICEF Reports 20 Million Children Face Annual Online Sexual Abuse
2h ago